N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT07639450
N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-29Est. Completion: 2028-08-31
Enrollment target: 114 participants Locations- GenesisCare Research, Saint Leonards, New South Wales, Australia
- San Clinical Trials Unit, Wahroonga, New South Wales, Australia
- Corner Edith & Platt Streets, , NSW 2298 Australia, Waratah, New South Wales, Australia
- Hunan Cancer Hospital, Changsha, Hunan, China
- Shanghai East Hospital, Shanghai, Shanghai Municipality, China
- Henan Cancer Hospital, Zhengzhou, Zhengzhou, China
Other microbiome trials you might be interested in
Malignant Brain NeoplasmMalignant Solid NeoplasmMultiple SclerosisNeuroendocrine TumorProstate Carcinoma
This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with…
Rochester, United StatesEst. completion Jan 18, 2027
Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast CancerBreast CancerMetastatic Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
HER2-negative Breast Cancer
This is an open-label, multicenter, phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, p…
Beijing, ChinaCompleted Apr 23, 2026
Endometrial CancerMalignant Solid Tumour
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxit…
Tucson, United StatesEst. completion Oct 15, 2027